OBJECTIVE: The objective of this study was to assess health care professionals' knowledge of evidence-based guidelines for the nonsurgical treatment of obesity. METHODS: A nationally representative sample of internists, family practitioners, obstetricians/gynecologists, and nurse practitioners completed a web-based survey between June 9 and July 1, 2016 (n = 1,506). RESULTS: Only 16% of respondents indicated that obesity counseling should be provided approximately twice monthly in an individual or group setting for at least 6 months, in accordance with United States Preventive Services Task Force and Centers for Medicare and Medicaid Services guidelines. Only 15% of respondents identified BMI ≥ 27 kg/m2 with an obesity-associated comorbid condition as the appropriate indication to prescribe pharmacotherapy for patients. Two-thirds of respondents indicated that it is appropriate to continue long-term pharmacotherapy under conditions inconsistent with evidence-based guidelines, with nearly one-quarter indicating that obesity medications should never be prescribed beyond 3 months regardless of weight loss. CONCLUSIONS: These findings suggest that provider understanding of appropriate clinical care for obesity is inconsistent with evidence-based recommendations. As coverage for behavioral counseling services and pharmacotherapy expands, it is imperative that health care professionals understand how to effectively leverage these treatment modalities to optimize health outcomes for patients with obesity.
OBJECTIVE: The objective of this study was to assess health care professionals' knowledge of evidence-based guidelines for the nonsurgical treatment of obesity. METHODS: A nationally representative sample of internists, family practitioners, obstetricians/gynecologists, and nurse practitioners completed a web-based survey between June 9 and July 1, 2016 (n = 1,506). RESULTS: Only 16% of respondents indicated that obesity counseling should be provided approximately twice monthly in an individual or group setting for at least 6 months, in accordance with United States Preventive Services Task Force and Centers for Medicare and Medicaid Services guidelines. Only 15% of respondents identified BMI ≥ 27 kg/m2 with an obesity-associated comorbid condition as the appropriate indication to prescribe pharmacotherapy for patients. Two-thirds of respondents indicated that it is appropriate to continue long-term pharmacotherapy under conditions inconsistent with evidence-based guidelines, with nearly one-quarter indicating that obesity medications should never be prescribed beyond 3 months regardless of weight loss. CONCLUSIONS: These findings suggest that provider understanding of appropriate clinical care for obesity is inconsistent with evidence-based recommendations. As coverage for behavioral counseling services and pharmacotherapy expands, it is imperative that health care professionals understand how to effectively leverage these treatment modalities to optimize health outcomes for patients with obesity.
Authors: Rasha A Almubark; Saleh Alqahtani; Arthur C Isnani; Ali Alqarni; Mahmoud Shams; Moataz Yahia; Assim A Alfadda Journal: Risk Manag Healthc Policy Date: 2022-06-03
Authors: Leo K Cheng; Nipuni D Nagahawatte; Recep Avci; Peng Du; Zhongming Liu; Niranchan Paskaranandavadivel Journal: Front Neurosci Date: 2021-04-22 Impact factor: 5.152
Authors: Andrew Stokes; Jason M Collins; Bethany F Grant; Chia-Wen Hsiao; Stephen S Johnston; Eric M Ammann; Kaitlyn M Berry; Cindy Tong; Robin F Scamuffa Journal: Obesity (Silver Spring) Date: 2018-04-06 Impact factor: 5.002
Authors: Ivana T Croghan; Sean M Phelan; David P Bradley; Katherine W Bauer; Steven M Bradley; Beret A Casey; Manpreet S Mundi; Ryan T Hurt; Darrell R Schroeder; Lila J Finney Rutten Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2018-09-28
Authors: Eulla Keimili Fernandes Ferreira Cavalheiro; Ana Beatriz Costa; Daniéle Hendler Salla; Mariella Reinol da Silva; Talita Farias Mendes; Larissa Espindola da Silva; Cristini da Rosa Turatti; Rafael Mariano de Bitencourt; Gislaine Tezza Rezin Journal: Cannabis Cannabinoid Res Date: 2021-07-09
Authors: Ivana T Croghan; Jon O Ebbert; Jane W Njeru; Tamim I Rajjo; Brian A Lynch; Ramona S DeJesus; Michael D Jensen; Karen M Fischer; Sean Phelan; Tara K Kaufman; Darrell R Schroeder; Lila J Finney Rutten; Sarah J Crane; Sidna M Tulledge-Scheitel Journal: J Prim Care Community Health Date: 2019 Jan-Dec